Welcome to our dedicated page for UNITEDHEALTH GROUP SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UNITEDHEALTH GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UNITEDHEALTH GROUP's regulatory disclosures and financial reporting.
UnitedHealth Group executive Patrick Hugh Conway, Chief Executive Officer of Optum, reported an open-market sale of 800 shares of UnitedHealth Group common stock. The shares were sold at a price of $355.00 per share. After this transaction, he directly holds 17,804.991 shares of common stock.
Fidelity Brokerage Services LLC submitted a Form 144 notice to sell up to 800 shares of Common Stock of UNH. The filing lists two tranches that vested: 301 shares on 02/20/2026 and 499 shares on 02/21/2026. The cover shows an aggregate amount of $284,000.00 and CUSIP 907675839 with the securities traded on NYSE.
UnitedHealth Group outlines its 2026 annual meeting agenda and broad governance, leadership and pay changes. Shareholders will vote on electing nine directors, an advisory Say‑on‑Pay, ratifying Deloitte & Touche as auditor, and a shareholder proposal on requiring an independent Board chair.
The company reports 2025 revenue of $447.6 billion, net earnings of $12.1 billion, fully diluted EPS of $13.23, ROE of 12.8% and an annual cash dividend of $8.84 per share. It plans to invest nearly $1.5 billion in AI initiatives in 2026 and at least that much again in 2027.
Governance updates include combining the CEO and Chair roles under Stephen Hemsley with a strengthened Lead Independent Director, creating a new Public Responsibility Committee, refreshing committee leadership and adding former FDA Commissioner Scott Gottlieb to the Board. Pay decisions include a $60 million cliff‑vesting stock option grant to the CEO, no annual bonus, and increasing CEO stock ownership requirements, while the CFO receives a $1 million salary, targeted 2x‑salary bonus, and $8 million in stock incentives plus a $1.2 million cash award.
UnitedHealth Group reported first quarter 2026 revenues of $111.7 billion, up 2% year-over-year, with earnings from operations of $9.0 billion and net margin of 5.6%. Diluted earnings were $6.90 per share and adjusted earnings were $7.23 per share, both slightly above the prior year.
The medical cost ratio improved to 83.9%, down 90 basis points, while the operating cost ratio rose to 13.8% as the company invested in people, technology and modernization. Cash flows from operations were $8.9 billion, or 1.4 times net income, and the debt-to-capital ratio was 42.9% as of March 31, 2026.
Management raised its full year 2026 earnings outlook to greater than $17.35 per share and adjusted earnings to greater than $18.25 per share. During the quarter, UnitedHealth agreed to acquire Alegeus Technologies, completed the sale of the Optum UK business with $400 million in net proceeds committed to the United Health Foundation, and put in place an arrangement to repurchase at least $2.0 billion of common stock by the end of the second quarter 2026.
HOOPER MICHELE J reported acquisition or exercise transactions in this Form 4 filing.
UnitedHealth Group director Michele J. Hooper received a grant of 206 deferred stock units of common stock on April 1, 2026 as regular quarterly compensation for Board service. The units are immediately vested but must be held until her Board service ends, bringing her direct holdings to 41,792 shares/units. This is a routine compensation-related equity award rather than an open-market purchase or sale.
MCNABB FREDERICK WILLIAM III reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC director Frederick William McNabb III received a grant of 388 deferred stock units of common stock as regular quarterly compensation for Board service. These units are immediately vested but must be held until he completes his service on the Board, and his direct holdings after the award total 15,162 shares.
Baker Charles D. reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC director Charles D. Baker received 343 deferred stock units of Common Stock as part of his regular quarterly board compensation. The units are immediately vested but must be held until he completes his service on the Board, bringing his direct holdings to 2,163 shares.
Gil Kristen reported acquisition or exercise transactions in this Form 4 filing.
UnitedHealth Group director Kristen Gil received 320 deferred stock units of common stock as regular quarterly compensation for Board service. These units are immediately vested but must be held until her Board service ends. Following this grant, she holds 2,403 shares directly and 3,800 shares indirectly through a trust.
Noseworthy John H reported acquisition or exercise transactions in this Form 4 filing.
Director John H. Noseworthy received a grant of 320 deferred stock units of UnitedHealth Group common stock as regular quarterly compensation for Board service. These deferred stock units are immediately vested but must be retained until he completes his service on the Board. Following this award, he directly holds 7,369 shares of common stock.
UnitedHealth Group director Paul R. Garcia reported routine equity compensation awards. On April 1, 2026, he acquired 206 deferred stock units and 137 shares of common stock as regular quarterly compensation for Board service. The deferred stock units are immediately vested but must be held until he completes Board service.
After these awards, Garcia directly holds 3,673 shares of UnitedHealth Group common stock. He also has indirect holdings through trusts, including 2,146 shares by a revocable trust, 45 shares by Trust 2, and 55 shares by Trust 3, reflecting additional beneficial interests reported in this filing.